Furosemide Wockhardt

Quick links to important sections

Furosemide Wockhardt

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Furosemide Wockhardt

Quick Facts

Property Description
Active ingredient Furosemid (INN)
Form Tablets, Oral solution, Solution for injection
Pharmacological class Loop diuretic (High-ceiling diuretic)
Common use Reduction of excess fluid volume
Origin Synthetic

Furosemide Wockhardt is a prescription-only medicine (POM) whose active compound is Furosemid, primarily used to promote the swift removal of salt and excess fluid from the body. It is classified as a diuretic and is recognized globally as an essential medicine for managing fluid retention.


What Type of Medicine is Furosemide Wockhardt?

Furosemide Wockhardt's active ingredient, Furosemid (INN), is a synthetic compound that belongs to the pharmacological class of loop diuretics, which are clinically recognized for their high efficacy. This preparation, manufactured by Wockhardt, is a single-ingredient product, focusing its therapeutic action entirely through the Furosemid compound, which is chemically identified as 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid.


Furosemid's General Purpose and Forms

The general therapeutic purpose of Furosemid is to quickly and effectively reduce the fluid volume in the body, which is a standard approach for managing conditions involving excessive fluid accumulation. Loop agents are capable of producing a greater diuresis (increased urine output) than other classes, such as thiazides. This property provides a reliable and potent method for addressing fluid overload in adult patients.

Furosemid is supplied by Wockhardt in several pharmaceutical preparations, including tablets for routine oral use, an oral solution suitable for patients who may have difficulty swallowing tablets, and a specialized solution for injection (ampoules/vials) for urgent parenteral (intravenous/intramuscular) administration.


How Does a Loop Diuretic Work (High-Level Concept)?

Loop diuretics work by directly interfering with the kidney's natural process of reclaiming water and salts. Furosemid acts to block the reabsorption of key salts—sodium, chloride, and potassium—causing them to remain in the urine. Water naturally follows these salts to maintain osmotic balance, leading to a substantial and reliable increased fluid output (diuresis) and achieving the necessary fluid volume reduction.

Regulatory References

  1. World Health Organization

What side effects are possible with Furosemide Wockhardt?

Possible side effects and safety information

Furosemide's official safety profile, as documented in government regulatory sources, establishes the potential for various adverse reactions, classified by frequency and grouped by the affected system-organ class.

Adverse Reaction Scope

The most frequent official regulatory classification is Very Common (ge 1/10), which includes fluid and electrolyte imbalance. This core safety characteristic encompasses potential changes such as hypovolemia (reduced blood volume), hyponatremia (low sodium), and hypokalemia (low potassium).

Adverse reactions are also noted across other systems, including the Ear and Labyrinth (e.g., tinnitus, hearing loss) and the Blood and Lymphatic System (e.g., thrombocytopenia, leukopenia).

Frequency Classification Examples (per regulatory sources)
Very Common Fluid and electrolyte imbalance, symptomatic hypotension
Uncommon Thrombocytopenia, deafness, visual disturbance
Rare Severe anaphylactic reactions, bone marrow depression, acute pancreatitis

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight Serious Adverse Reactions, including the potential for ototoxicity (hearing loss, sometimes irreversible) and severe dermatological conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Safety constraints define patient conditions where the drug should not be used. These include renal failure with anuria, hepatic coma/precoma, severe pre-existing hypokalemia or hyponatremia, and known hypersensitivity to Furosemide or sulfonamide derivatives.

Specific safety considerations are noted for certain populations. Elderly patients are identified as being at increased risk for dehydration, hypovolemia, and subsequent vascular thrombosis. For patients with pre-existing liver conditions, there is a documented risk of developing hepatic encephalopathy.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Furosemide Wockhardt, a potent diuretic, is documented in regulatory labeling as resulting primarily in profound diuresis and subsequent water and electrolyte depletion. The regulatory profile for overdose is centered on the risks associated with this severe fluid loss.

Documented Overdose Manifestations

Symptoms and signs listed in official documents include systemic effects such as dehydration, hypotension (low blood pressure), extreme thirst, weakness, lethargy, and muscle cramps. Laboratory findings of overdose consistently involve severe electrolyte imbalances like Hyponatremia and Hypokalemia, which are conditions resulting from excessive salt loss.

Severe Outcomes and Emergency Action

Serious, life-threatening outcomes documented in regulatory sources include circulatory collapse due to severe hypovolemia, vascular thrombosis and embolism, and the risk of seizures. In patients with pre-existing hepatic disease, severe fluid shifts may precipitate hepatic encephalopathy and coma.

Immediate emergency medical attention must be sought if severe manifestations such as collapse, seizure, or difficulty breathing occur. Treatment is officially designated as supportive and symptomatic, focused on the replacement of lost fluids and electrolytes, as no specific antidote is known.

Therapeutic Uses of Furosemide Wockhardt

What Furosemide Wockhardt Treats: Main Uses and Benefits

Furosemide Wockhardt is a commonly used therapeutic agent applied across domains where additional symptomatic support is needed by addressing the core issue of excessive fluid volume, a presentation associated with conditions marked by increased physiological stress.

The drug is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome.

The medication is utilized in clinical settings that involve acute or unstable symptom patterns, specifically addressing symptom clusters such as shortness of breath, severe systemic swelling (edema), and ascites (abdominal fluid). The primary therapeutic benefit is to address the symptoms related to systemic imbalance, which contributes to improved comfort and assists with maintaining functional stability. It also plays a role in managing the volume component of high blood pressure (hypertension).

“It is commonly used when symptoms intensify and supportive relief is needed, helping patients cope more steadily with difficult episodes.”


Quick Fact: Support for Fluid Overload Symptoms

The medication is commonly used for managing fluid overload, providing supportive relief when the physical burden of swelling and congestion creates noticeable physiological strain. It is relevant in scenarios involving symptoms of severe edema, lung congestion, or volume-dependent hypertension.

Eligibility and Restrictions for Use

Who can and cannot use Furosemide Wockhardt?

Regulatory documents define specific populations that are eligible, restricted, or prohibited from using Furosemide Wockhardt, based strictly on official labeling.

Populations That Must Not Use the Medicine (Contraindications)

Furosemide is contraindicated in patients with certain severe pre-existing conditions as stated in regulatory prescribing information. These conditions include the absence of urine formation (anuria), a history of severe hypersensitivity to Furosemide or its components, severe dehydration or hypovolaemia, and patients in hepatic coma or a pre-comatose state.


Eligibility and Conditional Use

Population Group Regulatory Status
Adult Patients Use is established for labeled indications.
Pediatric Patients Use is established, but requires conditional administration.
Older Adults Use is established, but requires caution and close monitoring for fluid/electrolyte balance.
Pregnancy/Lactation Generally not recommended; use only if potential benefit justifies documented risk, as stated in the label.
Organ Impairment Requires conditional use and caution in cases of severe liver impairment or pre-existing severe electrolyte imbalance (e.g., severe hypokalemia).
Comorbidities Use requires specific caution and monitoring in patients with conditions like Diabetes Mellitus, Gout, or Prostatic Hypertrophy.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Furosemide's interaction profile is primarily defined by the potential for pharmacodynamic potentiation and changes in the renal clearance of co-administered substances, as documented in regulatory information.


Key Interaction Categories

Interacting Product Category Key Constraint / Documented Effect
Ototoxic Agents (e.g., Aminoglycosides, Ethacrynic Acid, Cisplatin) Increased risk of ototoxicity; especially heightened with impaired renal function. The combination with Ethacrynic Acid is generally advised against.
Antihypertensive Agents (e.g., ACE Inhibitors, ARBs) Risk of severe hypotension and deterioration of renal function upon initial co-administration.
Lithium Furosemide reduces the renal clearance of lithium, leading to a high risk of lithium toxicity. The combination is generally not recommended.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) NSAIDs may antagonize the diuretic and blood pressure lowering effects of Furosemide and may increase the risk of renal function deterioration.

Administration and Timing Requirements

Co-administration with Sucralfate requires a separation of at least two hours to prevent documented interference with Furosemide's absorption. Furthermore, acid solutions, including other parenteral medications, must not be administered concurrently in the same infusion because they may cause the precipitation of Furosemide.

Population-Specific Note: The risk of ototoxicity with aminoglycoside antibiotics is specifically noted to be increased in patients with impaired renal function and hypoproteinemia.

Mechanism of Action

Specific Blockade of Renal Salt Transport

Furosemide's core mechanism is the competitive inhibition and blockade of the Na^+-K^+-2Cl^- cotransporter ( NKCC2). This highly specific target is situated on the membrane of cells in the Thick Ascending Limb of the kidney, a segment of the kidney tubule responsible for reclaiming a large portion of filtered salt. This molecular action immediately prevents the coupled transport of sodium, potassium, and chloride from the urine back into the bloodstream, which results in the retention of electrolytes within the tubule lumen.


Disrupting the Osmotic Driving Force

The consequence of blocking salt reabsorption is the disruption of the corticomedullary osmotic gradient, the fundamental concentration difference the kidney relies on to conserve water. This mechanistic step ensures that the large load of un-reabsorbed salts remains within the renal filtrate, which by the laws of osmosis, forces water to follow. This cascade produces an increase in urine output (diuresis), which leads to a net decrease in circulating and interstitial fluid volume.


️ Acute Effect on Vascular Capacitance

Before the fluid-loss mechanism is fully established, Furosemide engages a peripheral mechanism that causes an acute vasodilation (relaxation) of the venous system, an effect mediated independently of its renal actions. This immediate modulation of vascular tone reduces the volume and pressure of blood returning to the heart.

Dosage and Administration Information

How to Use Furosemide Wockhardt

Furosemide is available in several official forms, including oral tablets, an oral solution, and a solution for injection. The primary route for routine use is oral, while the intravenous (IV) route is utilized when a rapid effect is required or when oral absorption is impaired. Intravenous doses must be administered slowly, typically over one to two minutes, and should not exceed 4 mg per minute in adults.

Dosing and Frequency Principles

For routine oral use in adults, the initial dose for fluid retention ranges from 20 mg to 80 mg taken once daily. The dose may be adjusted based on response, and the maximum daily oral dose for resistant cases can be up to 600 mg. Oral dosing is generally scheduled in the morning or early in the day to prevent disruption from increased nighttime urination (nocturia). In acute settings, IV doses may be adjusted in increments of 20 mg no sooner than two hours after the previous dose.

Use in Specific Populations

Pediatric dosing is calculated based on body weight, starting at 1 mg per kilogram of body weight, with doses above 6 mg/ kg generally not recommended. For older adults, a lower starting dose and gradual adjustment are often required due to a potential increase in sensitivity to the medication's effects. When taking Furosemide orally, it can be taken with or without food, but should be separated from Sucralfate by at least two hours to ensure proper absorption.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Furosemide Wockhardt

Evidence for Fluid Retention in Congestive Heart Failure

Research exploring the use of Furosemide in conditions involving fluid overload, such as congestive heart failure (CHF), includes both numerous Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies have primarily focused on populations of adults, including the elderly, who are experiencing symptoms related to excess fluid, such as swelling and shortness of breath.

Researchers monitored physiological measures like overall body weight change and urine output (diuresis), along with measures related to hospital admission rates for heart failure and descriptions of patient functional status. Findings describe patterns observed in the studies related to the measured changes in fluid and salt excretion from the body.

Evidence for Fluid Retention in Liver and Kidney Disease

The evidence base for Furosemide in managing fluid retention associated with organ diseases, such as cirrhosis of the liver and certain types of renal disease (including nephrotic syndrome), includes smaller Comparative Trials and Observational Studies. Research examined populations experiencing fluid accumulation in the abdomen (ascites) or systemic swelling (edema) due to these specific conditions.

Studies monitored measures related to systemic imbalance, such as changes in ascites volume and change in body weight, along with monitoring key biochemical markers related to kidney health. Findings describe patterns observed in the studies related to the measured fluid and salt elimination, especially when Furosemide was used as part of a combination regimen with other diuretics.

What the Research Community Considers Uncertain or Still Developing

The scientific literature highlights several areas where certainty remains low or where more research is needed to fully contextualize the evidence for Furosemide. One key limitation is that some older studies have follow-up durations that were limited, making it difficult to fully understand the long-term impact on major health events like survival and chronic functional decline. Furthermore, comparative evidence for Furosemide against placebo in modern, large-scale chronic disease trials is often lacking, as ethical and regulatory standards often require comparison against an existing active standard of care.

Key Studies & References

  1. WHO Model List of Essential Medicines - 23rd List (2023) entry for Furosemide
  2. Pharmacological Management of Chronic Kidney Disease in Adults: NICE Guideline NG203 (Section on Edema Management)

Frequently Asked Questions (FAQ)

Common questions about Furosemide Wockhardt (FAQ)

Q: How long does it usually take for Furosemide Wockhardt to start working after taking a dose?

A: According to official product information, the onset of increased urine output (diuresis) is typically observed within one hour after taking the oral form of Furosemide. The medicine is generally understood to begin its action quickly.

Q: How long does the effect of one dose of Furosemide Wockhardt typically last?

A: Regulatory documents state that the diuretic effect—the period of increased fluid removal—of a single oral dose generally lasts between six and eight hours. This duration of action is reflected in the typical scheduling principles.

Q: Is frequent urination a side effect or a sign that Furosemide Wockhardt is working?

A: Increased urination, known as diuresis, is the intended and established mechanism of how Furosemide works. It is the expected action that helps the medicine reduce excess fluid volume in the body, rather than an unwanted side effect.

Q: What are the signs or symptoms of an electrolyte imbalance or dehydration to be aware of?

A: Official documents describe signs of excessive fluid or electrolyte loss, which can include feelings of increased thirst, dry mouth, weakness, drowsiness, muscle cramps or pain, and a fast or irregular heartbeat.

Q: Can Furosemide Wockhardt affect a person's blood sugar levels or is it a concern for people with diabetes?

A: Furosemide is known to potentially increase blood sugar (glucose) levels and may alter glucose tolerance. The official label notes that blood glucose monitoring is typically performed periodically in patients who have known diabetes or are otherwise susceptible.

Q: Is there a known interaction between Furosemide Wockhardt and alcohol?

A: Official information indicates that concurrent use of Furosemide and alcohol may increase the risk of orthostatic hypotension. This is a sudden drop in blood pressure that can cause dizziness or lightheadedness when changing body position, such as standing up.

Q: Does Furosemide Wockhardt increase sensitivity to sunlight (photosensitivity)?

A: Yes, photosensitivity, which is an increased sensitivity or reactivity of the skin to sunlight, is a documented dermatologic-hypersensitivity adverse reaction associated with Furosemide use.

Q: Can Furosemide Wockhardt lead to fatigue or tiredness?

A: While not listed as a standalone side effect, official labeling states that weakness and extreme tiredness can be experienced. These symptoms are documented as potential signs of excessive fluid and electrolyte loss, which is a very common adverse reaction to this medicine.

Q: Does Furosemide Wockhardt pose a risk for people with a history of Systemic Lupus Erythematosus (SLE)?

A: Official documentation notes that specific caution is advised regarding Furosemide use in patients with Systemic Lupus Erythematosus (SLE). This precaution is noted because the medication may potentially worsen the symptoms of the condition in some people.

Q: Can Furosemide Wockhardt interact with herbal supplements or over-the-counter remedies?

A: Regulatory guidance notes specific interactions, particularly with agents that can affect potassium, such as potassium supplements. For other herbal remedies and supplements, official information emphasizes the need for caution due to limited safety data regarding their combined effect.

Q: What is the risk of low sodium (hyponatremia) while using this drug?

A: The risk of hyponatremia (low blood sodium) is documented as a potential result of electrolyte depletion associated with Furosemide. This risk is documented, particularly in situations of higher doses or restricted salt intake.

Q: Does taking Furosemide Wockhardt require any specific dietary changes beyond fluid monitoring?

A: To support the medicine’s intended effect and manage the risk of electrolyte imbalance, official information related to use may discuss recommendations for diet. This commonly involves advice to limit high-sodium foods and possibly increase consumption of potassium-rich foods.

Q: Are there any long-term side effects associated with taking Furosemide Wockhardt for many years?

A: Continuous monitoring is recommended for patients on long-term Furosemide therapy to detect potential metabolic changes. Potential long-term issues noted in specific patient groups, such as infants, include the formation of kidney calcifications (nephrocalcinosis/nephrolithiasis).

Q: Is it common for Furosemide Wockhardt to cause confusion or memory problems in some people?

A: Confusion can occur as a symptom of severe fluid and electrolyte imbalance, which is a very common adverse reaction noted in the official safety profile of Furosemide. It is generally related to the body's reaction to excessive fluid loss.

Q: What is the role of fluid intake while taking Furosemide Wockhardt?

A: The primary role of fluid intake is to prevent excessive blood volume reduction and dehydration. It is understood that specific guidance on fluid consumption is typically provided by the patient’s healthcare team, as the medicine promotes fluid loss.

Q: Why might a patient be advised to avoid taking Furosemide Wockhardt late in the day?

A: The drug is typically scheduled for morning or early-day administration to align with the expected duration of effect. This timing helps prevent the period of increased urine output (diuresis) from interfering with nighttime sleep (nocturia).

Q: Does the body ever get 'used to' Furosemide Wockhardt (drug tolerance)?

A: Official clinical literature describes a pharmacological phenomenon where the body can initiate a compensatory retention of fluid and sodium in the kidney after the initial effect. This compensatory response may reduce the medicine's diuretic effect over time.

Q: What is the difference in effect between Furosemide Wockhardt tablets and IV (injection) use?

A: The main difference is the onset of action and the amount of drug that enters the bloodstream (bioavailability). The intravenous (IV) form is used when a rapid effect is required, and the IV dose must typically be lower than the oral tablet dose due to the difference in how the body absorbs the medicine.

Q: Is Furosemide Wockhardt used to treat conditions other than high blood pressure and fluid retention (edema)?

A: In addition to fluid retention (edema) and high blood pressure, official clinical protocols for acute settings may include its use for conditions like acute pulmonary edema and certain types of hypertensive crisis. It may also be used to manage severe electrolyte imbalances.

Q: What is the concern about taking Furosemide Wockhardt if I have pre-existing kidney problems?

A: The main concern is that Furosemide can cause dehydration and increase the level of nitrogenous waste products in the blood (azotemia). If signs of worsening kidney function occur (like increasing azotemia or low urine output), regulatory labeling indicates that discontinuation may be required.

Q: Is there a link between Furosemide Wockhardt use and changes to a person's vision?

A: Yes, changes to vision have been documented as an adverse reaction. These changes can include blurred vision or a yellow-tinged vision, which is known as xanthopsia.

Q: What are the symptoms of an overdose of Furosemide Wockhardt?

A: Symptoms of an overdose are directly related to extreme fluid and electrolyte loss. They may include extreme tiredness, dizziness, severe thirst, and dangerously low blood pressure.

Q: How does Furosemide Wockhardt compare to other loop diuretics like Bumetanide or Torasemide?

A: Furosemide is classified as a loop diuretic alongside medicines like Bumetanide and Torasemide. Factual differences exist in the drugs' properties, such as the oral dose equivalency and the duration of effect. For instance, Torasemide has been documented to have a longer half-life and higher oral absorption.

Q: Is it normal to have a dry mouth while taking Furosemide Wockhardt?

A: Dry mouth is a documented symptom that may be experienced while taking Furosemide. It is listed in official information as a potential sign of dehydration or a fluid and electrolyte imbalance, which is a very common adverse reaction to this medicine.

Q: Does Furosemide Wockhardt affect the results of routine blood or urine tests?

A: Yes, Furosemide is documented to affect the body's biochemistry, necessitating regular monitoring of markers. It requires checks of parameters such as serum electrolytes, creatinine, and blood urea nitrogen (BUN), and it can also alter the results of glucose tolerance tests.

Q: Is it necessary to stop taking Furosemide Wockhardt before surgery?

A: General pre-surgical protocols often describe the need to pause the use of diuretics, including Furosemide, on the morning of a procedure. This is typically due to the potential risk of dehydration and its effect on blood pressure control during surgery.

Q: Is Furosemide Wockhardt commonly used to treat fluid build-up associated with liver cirrhosis?

A: Yes, Furosemide is established for the treatment of fluid build-up (edema) associated with cirrhosis of the liver. For this condition, it is often used as part of a combination regimen with other types of diuretics.

Q: What are the concerns about Furosemide Wockhardt use in children?

A: Official guidance emphasizes that children typically require close monitoring for signs of severe fluid and electrolyte imbalances. Concerns in pediatric populations include the potential for specific kidney issues like nephrocalcinosis (kidney calcifications) and nephrolithiasis (kidney stones), especially in infants.

Q: Can taking Furosemide Wockhardt cause stomach upset or diarrhea?

A: Yes, gastrointestinal reactions are documented as possible adverse effects. These effects can include stomach cramping, nausea, vomiting, and diarrhea.

How should Furosemide Wockhardt be stored and disposed of?

Official Storage and Disposal Requirements

Furosemide tablets must be stored strictly according to regulatory mandates to ensure stability and public safety.

Requirement Condition
Storage Temperature Controlled Room Temperature: 20 to 25 C (68 to 77 F).
Container & Light Keep in a tight, light-resistant container, protected from light.
Product Stability Discolored tablets must not be used or dispensed.
Child Safety Store out of the sight and reach of children.

Disposal Instructions

Official regulations require that unused or expired Furosemide Wockhardt be disposed of in accordance with local requirements. The medication must not be thrown away via wastewater or standard household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Furosemide Wockhardt found in:

A-Z Index: